A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Public ClinicalTrials.gov record NCT03538028. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies
Study identification
- NCT ID
- NCT03538028
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Enrollment
- 22 participants
Conditions and interventions
Conditions
- Cervical Cancer
- Diffuse Large B-cell Lymphoma
- Esophageal Cancer
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])
- Hepatocellular Carcinoma
- MSI-high Colorectal Cancer
- Melanoma (Uveal Melanoma Excluded)
- Merkel Cell Carcinoma
- Mesothelioma
- Microsatellite Instability (MSI)-High Endometrial Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Renal Cell Carcinoma (RCC)
- Small Cell Lung Cancer (SCLC)
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Triple-negative Breast Cancer
- Urothelial Carcinoma
Interventions
- INCAGN02385 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 17, 2018
- Primary completion
- Oct 6, 2020
- Completion
- Oct 6, 2020
- Last update posted
- Oct 29, 2020
2018 – 2020
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Center | Los Angeles | California | 90025 | — |
| Hackensack Medical Center | Hackensack | New Jersey | 07601 | — |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03538028, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2020 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03538028 live on ClinicalTrials.gov.